<DOC>
	<DOCNO>NCT02107209</DOCNO>
	<brief_summary>The clinical utility bronchoscopic method achieve lung volume reduction evaluate patient advanced emphysema procedure uniformly safer surgical volume reduction . These include one-way valve , bronchial occlusive device collapse emphysematous region lung bronchial fenestration bypass stent improve expiratory flow , wire coil implant compress airway thermal vapor ablation cause acute injury subsequent fibrosis reduction volume .</brief_summary>
	<brief_title>Low Cost Biological Lung Volume Reduction Therapy Advanced Emphysema</brief_title>
	<detailed_description>Biologic lung volume reduction ( BioLVR ) : novel endobronchial approach , use Biological agent aim reduce lung volume block emphysematous area rapidly polymerize sealant . The mechanism action involve resorption atelectasis airway occlusion , subsequent airspace inflammation , remodel . This remodel lead scar induces contraction lung parenchyma functional volume reduction expect within 6-8 week . Biological lung volume reduction occur independent presence absence collateral ventilation .</detailed_description>
	<mesh_term>Emphysema</mesh_term>
	<mesh_term>Pulmonary Emphysema</mesh_term>
	<criteria>1 . Emphysema determine HRCT chest : .Persistent symptom ( i.e . baseline Modified Medical Research Council dyspnea ( MRC ) score &gt; 2 despite medical therapy ) . FEV1 /FVC &lt; 70 % FEV1 20 % 50 % ( Sever sever airflow limitation accord GOLD 2013 ) . Hyperinflation ( total lung capacity ( TLC ) &gt; 110 % pred residual volume/total lung capacity ( RV/TLC ) &gt; 120 % pred . 2 . Patients candidate refused lung volume reduction surgery . 3 . Age &gt; 40 yr . 1 . Airflow limitation FEV1 &lt; 20 % . 2 . DLCO &lt; 20 % . 3 . Current smoker . 4 . Patients candidate FOB .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>